187 related articles for article (PubMed ID: 17877614)
1. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Lescoat G; Chantrel-Groussard K; Pasdeloup N; Nick H; Brissot P; Gaboriau F
Cell Prolif; 2007 Oct; 40(5):755-67. PubMed ID: 17877614
[TBL] [Abstract][Full Text] [Related]
2. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
[TBL] [Abstract][Full Text] [Related]
3. The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.
Chantrel-Groussard K; Gaboriau F; Pasdeloup N; Havouis R; Nick H; Pierre JL; Brissot P; Lescoat G
Eur J Pharmacol; 2006 Jul; 541(3):129-37. PubMed ID: 16765341
[TBL] [Abstract][Full Text] [Related]
4. Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.
Gaboriau F; Chantrel-Groussard K; Rakba N; Loyer P; Pasdeloup N; Hider RC; Brissot P; Lescoat G
Biochem Pharmacol; 2004 Apr; 67(8):1479-87. PubMed ID: 15041465
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effect of deferiprone on the Hep G2 cell line.
Chenoufi N; Drénou B; Loréal O; Pigeon C; Brissot P; Lescoat G
Biochem Pharmacol; 1998 Aug; 56(4):431-7. PubMed ID: 9763218
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cell proliferation and polyamine metabolism in rat liver cell cultures by the iron chelator O-trensox.
Gaboriau F; Laupen-Chassay C; Pasdeloup N; Pierre JL; Brissot P; Lescoat G
Biometals; 2006 Dec; 19(6):623-32. PubMed ID: 16944279
[TBL] [Abstract][Full Text] [Related]
7. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
8. In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.
Sonnet P; Mullié C
Exp Parasitol; 2011 May; 128(1):26-31. PubMed ID: 21295029
[TBL] [Abstract][Full Text] [Related]
9. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Rouan MC; Marfil F; Mangoni P; Séchaud R; Humbert H; Maurer G
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):203-13. PubMed ID: 11393706
[TBL] [Abstract][Full Text] [Related]
10. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
Glickstein H; El RB; Shvartsman M; Cabantchik ZI
Blood; 2005 Nov; 106(9):3242-50. PubMed ID: 16020512
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
12. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human.
Weiss HM; Fresneau M; Camenisch GP; Kretz O; Gross G
Drug Metab Dispos; 2006 Jun; 34(6):971-5. PubMed ID: 16531476
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes.
Pires VS; Gaboriau F; Guillon J; Nascimento S; Dassonville A; Lescoat G; Desplat V; Rochette J; Jarry C; Sonnet P
J Enzyme Inhib Med Chem; 2006 Jun; 21(3):261-70. PubMed ID: 16918073
[TBL] [Abstract][Full Text] [Related]
15. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
Chua AC; Ingram HA; Raymond KN; Baker E
Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
[TBL] [Abstract][Full Text] [Related]
16. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
17. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
18. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis.
Georgiou NA; van der Bruggen T; Oudshoorn M; Hider RC; Marx JJ; van Asbeck BS
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():91-6. PubMed ID: 11886438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
